You are here: Home: BCU 7|2003: A CME Audio Series and Activity

Breast Cancer Update: A CME Audio Series and Activity

STATEMENT OF NEED/TARGET AUDIENCE

Breast cancer is one of the most rapidly evolving fields in medical oncology. Published results from a plethora of ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care - including the option of clinical trial participation - the practicing medical oncologist must be well-informed of these advances. To bridge the gap between research and patient care, Breast Cancer Update uses one-on-one discussions with leading oncology investigators. By providing access to the latest research developments and expert perspectives, this CME program assists medical oncologists in the formulation of up-to-date clinical management strategies.

GLOBAL LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

  • Critically evaluate the clinical implications of emerging clinical trial data in breast cancer treatment.
  • Describe and implement an algorithm for HER2 testing and treatment of patients with HER2-positive breast cancer.
  • Develop and explain a management strategy for treatment of ER-positive breast cancer in the adjuvant, neoadjuvant and metastatic settings.
  • Develop and explain a management strategy for treatment of ER-negative breast cancer in the adjuvant, neoadjuvant and metastatic settings.
  • Counsel postmenopausal patients with ER-positive breast cancer about the risks and benefits of aromatase inhibitors in the adjuvant setting.
  • Evaluate the emerging data on dose-dense chemotherapy and explain its relevance to patients.

SPECIFIC LEARNING OBJECTIVES FOR ISSUE 7

Upon completion of this activity, participants should be able to:

  • Discuss the efficacy and tolerability of the trastuzumab/taxane/carboplatin combination, and the ongoing related trials to assist in the management of select patients with HER2-positive disease in the metastatic setting.
  • Describe the efficacy and tolerability of fulvestrant in order to counsel patients with ER-positive metastatic disease about therapy options.
  • Evaluate the Women's Health Initiative trial results to counsel women regarding the beneficial and detrimental effects associated with menopausal hormone therapy.
  • Evaluate novel data regarding dose-dense scheduling of chemotherapy and the use of taxanes in the adjuvant setting.
  • Describe a management strategy for the use of chemotherapy and endocrine therapy in women with metastatic disease.

ACCREDITATION STATEMENT

NL Communications is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

NL Communications designates this educational activity for a maximum of 3.25 category 1 credits towards the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent on the activity.

Table of Contents Top of Page

 

 

Home · Search

 
Editor’s Note: Data-driven
 
Howard A Burris III, MD
- Select publications
 
Richard M Elledge, MD
- Select publications
 
Rowan T Chlebowski, MD, PhD
- Select publications
 
Vicente Valero, MD
- Select publications
 
Editor's office
Faculty Disclosures
Home · Contact us
Terms of use and general disclaimer